Based on the results of our study, we foresee the systemic use (i.e. intravenous injection) of Chrdl1; not only immediately after MI to block fibrosis pathways from starting but also several days after MI to decrease active and ongoing fibrillogenesis thus reducing scar size and excessive CF. Here, CHRDL1 is linked to myocardial infarction.